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Abstract
Binding of plasminogen to fibrin and cell surfaces is essential for fibrinolysis and pericellular proteolysis. We used surface plasmon
resonance and enzyme kinetic analyses to study the effect of two mAbs (A10.2, CPL15) on plasminogen binding and activation at fibrin
surfaces. A10.2 is directed against the lysine-binding site (LBS) of kringle 4, whereas CPL15 recognises a region in kringle 1 outside the
LBS. In the presence of CPL15 and A10.2 mAbs, binding of plasminogen (Kd = 1.16F 0.22 Amol/l) to fibrin was characterised by a mAb
concentration-dependent bell-shaped isotherm. A progressive increase in the concentration of mAbs at the surface was also detected, and
reached a plateau corresponding to the maximum of plasminogen bound. These data indicated that at low mAb concentration, bivalent
plasminogen–mAb–plasminogen ternary complexes are formed, whereas at high mAb concentration, a progressive shift to monovalent
plasminogen–mAb binary complexes is observed. Plasmin formation in the presence of mAbs followed a similar bell-shaped profile.
Monovalent Fab fragments of mAb A10.2 showed no effect on the binding of plasminogen, confirming the notion that a bivalent mAb
interaction is essential to increase plasminogen binding and activation at the surface of fibrin.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Native plasminogen is a single-chain polypeptide of 791
amino acids consisting of NH2-terminal glutamic acid
followed by a tandem of five domains called kringle, a
sequence containing the cleavage site (Arg561–Val562) and
a serine protease domain [1]. Plasminogen is the inactive
precursor of the protease plasmin, which plays a pivotal role
in fibrinolysis, cell migration and tissue remodeling [2].
Plasminogen binds to fibrin blood cells (neutrophils, mono-
cytes) [3–5] and vascular cells [6] through the lysine-bind-
ing sites (LBSs) of kringle-1 and kringle 4 domains [7].
These interactions markedly increase the susceptibility of
plasminogen to proteolytic activation by tissue- (t-PA) and
urokinase-type plasminogen activators on fibrin and cell
surfaces, respectively [8,9]. This process is mainly regulated
by a2-antiplasmin and plasminogen activator inhibitor type
1. Other factors may, however, interfere with this mecha-
nism. Among them, the lipoprotein Lp(a) [10], a highly
atherogenic lipoprotein particle, which possesses multiple
copies of plasminogen-like kringle 4 in its apolipopro-
tein(a), apo(a), moiety [11]. Lp(a) inhibits plasmin forma-
tion by competing with plasminogen for binding sites on
fibrin and cell surfaces [12,13]. On the other hand, it has
been demonstrated that the interaction of monoclonal anti-
bodies with the low- or high-affinity LBSs of plasminogen
may result in conformational changes yielding the plasmi-
nogen more susceptible to activation by plasminogen acti-
vators [14,15]. It is conceivable, however, that an additional
mechanism intrinsic to antibody structure, antibody biva-
lency, may explain the increase in plasmin formation. A
number of reports have shown for instance that antibody
bivalency is an absolute requirement for the enhanced
binding of prothrombin and h2-glycoprotein I to phospho-
lipids [16–22]. We hypothesise that mAbs directed against
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plasminogen may increase its binding to fibrin through a
similar mechanism. The availability of the monoclonal anti-
bodies A10.2 that interacts with the LBS of plasminogen
kringle 4 [23] and CPL15 that recognises plasminogen
kringle 1 [24], prompted us to investigate their effect on
plasminogen binding under static and flow conditions using
surface plasmon resonance (SPR) analysis. In the present
work, we show that these mAbs enhance plasmin formation
and fibrinolysis through the formation of bivalent plasmino-
gen–mAb–plasminogen complexes that result in increased
plasminogen binding to fibrin surfaces.
2. Materials and methods
2.1. Reagents
All of the chemicals used were of the best reagent grade
commercially available. Other products were purchased
from the following sources. Bovine serum albumin (BSA)
from Eurobio (Les Ulis, France); (methylmalonyl)hydroxy-
prolylarginine-p-nitroanilide (CBS 0065) from Diagnostica
Stago (Asnie`res, France); 6-aminohexanoic acid (6-Ahx)
and papain from Sigma (St. Louis, MO, USA); nitrocellu-
lose sheets from Sartorius (Palaiseau, France). Composition
of buffers: buffer A, 50 mmol/l sodium phosphate, pH 7.4,
80 mmol/l NaCl, 0.01% Tween 20, and 0.01% NaN3; assay
buffer, buffer A containing 2 mg of BSA/ml. HBS buffer for
Biacore experiments consisted of 10 mmol/l Hepes, pH 7.4,
150 mmol/l NaCl, and 0.05% (v/v) surfactant P20.
2.2. Protein purification and radioiodination
Fibrinogen was purified from fresh-frozen human plasma
supplemented with proteinase inhibitors (100 k.i.u./ml apro-
tinin, 2 mmol/l phenylmethysulphonyl fluoride PMSF, 1
Amol/l H-D-Phe-Pro-Arg-CH2CI, 200 mmol/l 6-Ahx, 10
Amol/l p-nitrophenyl-pV-guanidinobenzoate, and 4 mmol/l
benzamidine, final concentrations), as previously described
[25] with minor modifications [26]. In brief, the procedure
included two glycine precipitations of proteins remaining in
the soluble phase of plasma precipitated twice with BaSO4,
followed by chromatography on a Sepharose 6B column in
50 mmol/l phosphate buffer, pH 7.4, containing 0.5 mol/l
NaCl, 2 mmol/l EDTA and all aforementioned inhibitors
except 6-Ahx. Further purification was obtained by affinity
chromatography on lysine-Sepharose 4B, gelatine-Ultrogel
and organomercurial agarose. Fibrinogen was concentrated
by precipitation with glycine (0.16 g/l), extensively dialysed
against 0.1 mol/l phosphate buffer, pH 7.4, containing 0.3
mol/l NaCl, separated into aliquots (12 mg/ml) and stored at
 80 jC. The purified fibrinogen was free from von
Willebrand factor, plasminogen, fibronectin and factor XIII
as determined with enzyme-linked immunosorbent assays
specific for these proteins; the absence of plasminogen or
plasmin was confirmed by incubating for 72 h at 37 jC
fibrin–agar plates prepared with the purified product sup-
plemented or not with t-PA. Fibrinogen was more than 98%
clottable and appeared homogeneous by SDS-polyacryla-
mide gel electrophoresis. Plasminogen was purified from
fresh-frozen human plasma supplemented with proteinase
inhibitors as described [27]. Elastase-derived plasminogen
fragments kringle 1 + 2 + 3, and kringle 4 were prepared
according to Sottrup-Jensen et al. [28] with minor modifi-
cations [29]. Human recombinant apo(a) was prepared and
isolated as described [23]. Human a-thrombin purified as
previously described [30] was kindly provided by M.C.
Gullin (Faculte´ X. Bichat, University of Paris). Protein
concentration was estimated by measuring the absorbance
at 280 nm and using relative molecular masses and extinc-
tion coefficients (e280 nm, cm
1 mg/ml ) of 340000 and 15.1 for
fibrinogen [31], 93000 and 16.8 for plasminogen [32],
10000 and 3.1 for kringle 4, 35000 and 8.08 for kringle
1 + 2 + 3, 36500 and 1.83 for a-thrombin [33]. Human t-PA
( > 95% single-chain) purified from Bowes melanoma cell-
conditioned medium on immobilized monoclonal antibody
anti-t-PA was from Biopool (Uppsala, Sweden); it had a
specific activity of 680000 IU/mg.
Plasminogen was radioiodinated with Na[125I] using the
lodogenk method [34], an iodination time of 4 min at 4 jC
and removal of free 125I by molecular sieving on a PD-10
Sephadex column (Pharmacia, Uppsala, Sweden). The spe-
cific radioactivity obtained was 3 nCi/ng.
2.3. Monoclonal antibodies
Murine monoclonal antibodies A10.2 and CPL15 were
prepared as previously described using conventional hybrid-
oma technology. MAb A10.2 is an IgG1 directed against the
LBS of plasminogen kringle 4 and plasminogen-like KIV-
10 of apo(a) that was raised by immunization of BALB/c
mice with recombinant apo(a) [23]. CPL15 is an IgG1 mAb
directed against the kringle 1 of plasminogen as indicated by
its reactivity against the plasminogen fragment K1 + 2 + 3
and plasmin–a2-antiplasmin complexes [24]. Y18, an IgM
mAb that recognises the Aa stretch 1–51 of human fibri-
nogen [35], was kindly provided by Dr. W. Nieuwenhuizen
(Gaubius Institut, Leyden, The Netherlands).
2.4. Preparation of Fab fragments
The IgG fraction of mAbs was isolated from a hollow
fiber bioreactor supernatant by Hi-Trap r-protein-A sephar-
ose (Pharmacia) affinity chromatography as described by Ey
et al. [36], with minor modifications. The IgG (20 mg) of
mAb A10.2 was digested for 30 min at 37 jC with papain
(mass ratio papain/IgG, 1:100) in 50 mmol/l phosphate
buffer, pH 7.4, containing 50 mmol/l cystein. Before starting
the reaction, the mixture was flushed with nitrogen to
prevent cystein oxidation. The reaction was terminated by
adding 50 mmol/l iodoacetamide. The mixture was then
dialysed against 100 mmol/l sodium citrate buffer, pH 5.
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The digested material was chromatographed on a Hi-Trap r-
protein-A sepharose, which retained most of the Fc frag-
ments and undigested IgG. Further purification of the flow
through protein peak was obtained by gel filtration on an
HR-Sephadex 200 column (Pharmacia) equilibrated with the
same buffer. The purified Fab migrated as a single protein
band of 50000 relative molecular mass in non-reducing
7.5% polyacrylamide gels.
2.5. SPR analyses
Interactions between plasminogen, fibrin and the mAbs
were investigated by real-time biospecific analysis based on
SPR measurements using a BIAcoreR 2000 system and
reagents from Biacore (Uppsala, Sweden), including the
amine coupling kit (NHS, N-hydroxysuccinimide; EDC, N-
ethyl-NV-(3-dimethyllaminopropyl) carbodiimide hydro-
chloride; ethanolamine hydrochloride), an immunosorbent
purified rabbit IgG directed against mouse Fc (RamFc) and
sensor chips CM5 and pioneer C1. The change in refractive
index induced by the association and dissociation of pro-
teins interacting with the sensor surface as a function of time
is expressed in resonance units (RU) [37]. A relationship in
which 1000 RU corresponds approximately to a surface
mass change of 1 ng protein/mm2 has been established [38]
that may reasonably be considered to apply to all proteins as
they display similar specific refractive index increments. All
experiments were performed at 25 jC with a flow rate of 10
Al/min unless otherwise indicated.
2.5.1. Determination of affinity of mAbs for plasminogen in
fluid phase
Interaction of plasminogen with immobilised mAbs
A10.2 and CPL15 was determined using a CM5-RamFc
sensor chip prepared as described [39]. Briefly, activation of
the CM5 sensor chip as indicated above was followed by
immobilisation of the RamFc (70 Al at 40 Ag/ml in 10
mmol/l sodium acetate, pH 4.8) and blocking of remaining
unreacted active NHS-ester groups with 1 mol/l ethanol-
amine hydrochloride. Typical immobilisations yielded
f 13500 RU corresponding to 13.5 ng (90 fmol/mm2) of
RamFc bound to the biosensor surface. An analytical
immunocapture cycle consisted of injection of mAbs (1
Ag/ml) followed by a 10-Al injection of plasminogen or its
fragments (0–500 nmol/l), buffer flow for dissociation, and
regeneration of the surface with 10 Al 50 mmol/l HCl. The
amount bound (RU) at equilibrium was recorded and fitted
to the Langmuir equation as a function of plasminogen
concentration to calculate affinity constant (Kd) and max-
imum bound (Bmax). Affinity constants were also calculated
from kinetic data.
2.5.2. Preparation of fibrin sensor chip surfaces
Fibrinogen was first immobilised on C1 sensor chips as
follows. The sensor surface was activated with a mixture of
NHS/EDC according to the manufacturer’s instructions. The
C1 sensor chip is a carboxymethylated flat surface with no
dextran matrix that was further treated with 20 mmol/l 1,6-
diaminehexane followed by 2.5% polymerised glutaralde-
hyde used as linker/spacer. Fibrinogen (70 Al at 50 Ag/ml in
10 mmol/l sodium acetate, pH 5.5) was then covalently
coupled onto three flow cells via primary amino groups at a
flow rate of 10 Al/min at 25 jC. Unreacted amino groups in
fibrinogen-coated cells were inactivated by injecting 40 Al
of 1 mol/l ethanolamine hydrochloride. The remaining
uncoated flow cell was blocked with ethanolamine as above
with no fibrinogen added, to serve as a control for the
contribution of the bulk refractive index. The SPR response
for the immobilisation of fibrinogen was 17000F 1000 RU
(50F 3 fmol/mm2) at the concentration used.
On-chip digestion of immobilised fibrinogen was per-
formed by injecting active a-thrombin (100 nmol/l) at a
flow of 2 Al/min for 20 min. The cleavage of fibrinopeptide
A by a-thrombin was verified by measuring the binding of
Y18, a monoclonal antibody directed against an epitope
comprised in the Aa 1–51 sequence of human fibrinogen
[35]. A resonance response of f 13700 RU was finally
obtained equivalent to f 43 pmol of immobilised fibrin per
square millimeter.
2.5.3. Interactions between plasminogen, monoclonal
antibodies and fibrin surfaces
The fibrin sensor chip was equilibrated with 10 mmol/l
Hepes, pH 7.5, 0.15 mol/l NaCl, 0.003% Tween 20 for
several hours at 5 Al/min before collection of experimental
data. Functionality of the fibrin sensor chip was first
assessed by measuring the specific binding of plasminogen
(0.01–20 Amol/l), or r-apo(a) (0.007–1 Amol/l) previously
treated with 1 Amol/l H-D-Val-Pro-Lys-CH2Cl (VPK). A
10-Al volume of the indicated concentrations was injected at
a flow rate of 10 Al/min. The fibrin surface was regenerated
after each binding interaction with 0.2 mol/l 6-Ahx in HBS
at a flow rate of 30 Al/min for 30 s. Specificity of the
binding was determined by injecting selected concentrations
of either plasminogen or apo(a) previously incubated with
varying concentrations of 6-Ahx. The reciprocal of the
measured response (1/RU) was then plotted against the
concentration of 6-Ahx and the inhibition constant calcu-
lated at the intersection of the linear regression analysis for
each analyte concentration. To investigate the effect of
mAbs on the binding of plasminogen to fibrin, a 25-nmol/
l final plasminogen concentration and 0–250 nmol/l mAbs
IgG or Fab fragment were incubated for 15 min at 22 jC
and then injected onto the fibrin sensor chip. Elution of
plasminogen–mAbs complexes was performed with 0.2
mol/l 6-Ahx as indicated above. The response for the
reference uncoated flow cell was subtracted from that of
the coated cells to correct for bulk refractive index changes,
non-specific binding, and instrument drift. The flow cells
with immobilised fibrin showed good stability and no
significant decrease in bound fibrin was observed during
the course of the experiments.
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2.6. Effect of mAbs on plasmin formation at the surface of
fibrin
Fibrin surfaces were prepared as described [27]. Briefly,
fibrinogen was covalently bound to stable polyglutaralde-
hyde derivatives and was transformed into a fibrin surface
by treatment with a-thrombin. This procedure is similar to
the one used for the preparation of fibrin surfaces on C1
sensor chips except for the use of multi-well polyvynil
chloride plates as solid support. The activation of plasmi-
nogen by t-PA on these fibrin plates was performed as
indicated elsewhere [40], with minor modifications. Briefly,
a solid-phase fibrin plate was washed three times with
binding buffer, and 50 Al per well of the same buffer
containing 100 IU/ml t-PA was incubated for 1 h at 37
jC. The plate was then washed twice with assay buffer to
remove unbound proteins, and the activation was started by
adding 50 Al per well of plasminogen (150 nmol/l) alone or
supplemented with mAbs A10.2 or CPL15 IgG or Fab
fragment at three different concentrations. A mouse mye-
loma IgG (P3X63) was used as a control. To quantitate the
amount of fibrin-bound plasmin(ogen), experiments were
performed in the presence of a trace amount of 125I-Glu-
plasminogen (4–8 nmol/l, final concentration). The activa-
tion was performed in a series of three wells and was
monitored at 37 jC for 1 h. Every 15 min, the reaction
was stopped by removing the fluid phase and washing the
wells with assay buffer. Fibrin-bound plasmin was then
detected by measuring its amidolytic activity or counting
the radioactivity as follows. A volume of 50 Al of 1.5 mmol/
l CBS 0065 in assay buffer/well was added and the rate of p-
nitroanilide hydrolysis was measured from the change in
absorbance at a double-wavelength absorbance ratio (A405/
A490) with a microtitration plate counter (MR 5000, Dyna-
tech) equipped with a thermostatic device to maintain
temperature at a constant 37 jC. Since the substrate is
added after washing off proteins in solution, the increase
in absorbance at 405 nm is linear with time and the slope
(DA405/min) proportional to the amount of plasmin gener-
ated during the activation period. Initial rates of p-nitroani-
line release from CBS 0065 were therefore transformed into
femtomoles of plasmin bound per well using the following
equations.
½plasmin ¼ v½Km þ ½CBS 0065=Kcat½CBS 0065 ð1Þ
as described by Fleury et al. [41]. For that purpose, values of
A405 nm/min were converted to moles per second using a
molar extinction coefficient for p-nitroaniline of 9920 mol
l  1 cm  1 adapted to a 50-Al/well pathway, and the
following values for the concentration of CBS 0065 = 0.75
mmol/l, Km = 0.661 mmol/l, and Kcat = 25.42 s
 1. At the
end of the kinetic measurement, the plate was washed three
times with assay buffer, and radioactivity in the wells
counted in a gamma radiation counter. The total amount
of plasmin(ogen) derivatives bound to fibrin was reported in
picomoles of protein bound per well using the molar radio-
activiy of the plasminogen activation solution.
In parallel experiments, the fibrin surface was probed
with a peroxidase-conjugated goat anti-mouse IgG antibody
(Dako, Denmark) to detect possible binding of the mAbs to
the fibrin surface. A 1-mg/ml solution of 2,2V-azinobis 3-
ethyl-benzthiazoline-6 sulfonic acid (ABTS, Roche Phar-
maceuticals, Germany) was used as a substrate for color
development. The absorbance of the developing solution
was measured at A405 nm.
2.7. Analysis of SPR binding data
For a bimolecular interaction between the immobilised
ligand and the soluble analyte, the relative response of the
optical biosensor at time t is proportional to the amount of
ligand/analyte complex formed. Since (1) the concentration
of immobilised ligand (nanograms protein per square milli-
meter) is constant, and (2) the amount of complexes formed
is a function of both the free solute concentration and the
affinity of the interaction, a simple thermodynamic analysis
can be used to characterize the adsorption phenomenon. To
avoid the distortion error that is introduced by analysis of
linearly transformed data, the results have been interpreted
in terms of the simplest form of this relationship, the
rectangular hyperbolic Langmuir adsorption equation for
bimolecular single-site interactions at heterogeneous inter-
faces [42].
Req ¼ RmaxKa
1þ KaL þ ðbÞL ¼
RmaxL
Kd þ L þ ðbÞL ð2Þ
where Req, the SPR response, is a function of L, the solute
concentration, Rmax is the maximum SPR response for a
flow cell that has its immobilised ligand fully saturated with
analyte, and Ka and Kd the equilibrium and dissociation
constants, respectively. (b) is a proportionality constant
representing nonspecific binding. A correct fit of data to
this equation using non-linear regression analysis (Kalleida-
graph software) allows quantitation of both the maximum
bound (Bmax) and the dissociation constants Kd =Ka
 1.
Response plateau values, obtained after binding has reached
equilibrium, were plotted versus the concentration of ana-
lyte that were flowed into the sensor chip channels. If the
simple Langmuir relationship fits correctly a plot of the
measured response versus ligand concentration, then the
binding interaction obeys a one-to-one binding model, and
the kinetic constants can be determined using this model
[43]. The theory of kinetic measurement of this interaction
has been well established [44,45]. The evaluation of asso-
ciation (Kon) and the dissociation (Koff) rate constants was
performed using fitting procedures in the BiaEval 3.0
program (Biacore) applying the 1:1 Langmuir binding
model. Consistency of the data was examined by compar-
ison of the equilibrium constants with the thermodynamic
analysis using the Langmuir relationship.
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3. Results
3.1. Biosensor analysis of specificity and affinity of mAbs
for plasminogen
Plasminogen and its fragments at varying concentrations
were flowed onto RamFc-immobilised mAbs and data were
fitted to the Langmuir model assuming a 1:1 binding
interaction. Results are shown in Table 1. A dissociation
constant of 13F 0.65 and 32F 0.15 nmol/l was calculated
for A10.2 and CPL15 mAbs, respectively. These values
were in good agreement with those obtained from kinetic
data (not shown). In experiments performed with isolated
elastase-derived plasminogen fragments, it was demonstra-
ted that mAb CPL15 recognises an epitope present in
fragment K1 + 2 + 3 (Kd = 5.8F 0.5 nmol/l), whereas mAb
A10.2 recognises the LBS of fragment K4 (Kd = 5.6F 0.6
nmol/l).
3.2. Interactions between plasminogen and mAbs on a fibrin
sensor chip
A fibrin surface sensor chip was used to examine the
binding characteristics of plasminogen in the presence of
mAbs A10.2 and CPL15 by SPR analysis. This technique
was used because it detects adsorption of protein complexes
onto a sensor chip surface in real time as a function of the
concentration of one of the components. For this purpose,
fibrinogen was immobilised onto C1 sensor chips and then
transformed into fibrin by flowing active a-thrombin. As
digestion of fibrinogen immobilised on the sensor chip
progressed, the resonance response gradually lowered
(Fig. 1). The sensorgram thus obtained clearly differed from
sensorgrams of simple analyte– ligand association. A
marked decrease in the refractive index was observed as a
function of time of a-thrombin injection indicating loss of
material, due to on-chip digestion. Fibrinogen to fibrin
conversion, loss of fibrinopeptides, was verified by decrease
in reactivity with Y18, a mAb that specifically recognises
fibrinopeptide A in fibrinogen. Reactivity of mAb Y18 with
the sensor chip was no longer detectable after five succes-
sive injections of a-thrombin (Fig. 1, inset) indicating the
formation of a fibrin monolayer. This surface was function-
ally characterised by measuring binding of proteins, plasmi-
nogen and a recombinant apo(a), known to specifically
interact with fibrin through LBSs. These interactions
reached saturation, were specifically inhibited by 6-Ahx
[Ki = 0.112 mmol/l for plasminogen and Ki = 0.5 mmol/l
for r-apo(a)] and were characterised by single-site binding
as indicated by plots of the binding response at equilibrium
versus the concentration of analyte according to the Lang-
muir equation (Fig. 2). The dissociation constants calculated
for plasminogen, Kd = 1.16F 0.22 Amol/l, and for apo(a),
Kd = 54F 5 nmol/l, are in agreement with previously pub-
lished data [12,27,29] in which fibrin was immobilised on
multi-well plates using polymerised glutaraldehyde as a
linker. This procedure has been previously proven to result
in a fibrin monolayer that mimics a fibrin clot surface with
regard to plasminogen binding and activation in a static
system [27,40,41]. The finding of similar results in poly-
glutaraldehyde-activated C1 sensor chips indicates that
binding of plasminogen preceding its activation on fibrin
in a static system and binding of plasminogen observed in
real time under flow conditions (see below) obeys a similar
mechanism.
3.3. Effects of mAbs on Glu plasminogen binding to a fibrin
sensor chip
To test the effect of mAbs CPL15 and A10.2 on binding
of plasminogen to the fibrin sensor chip, a concentration of
25 nmol/l of plasminogen was chosen from the binding
isotherm shown in Fig. 2. This concentration produces a
clearly measurable sensor response (f 18 RU). Fig. 3,
main graph, shows adsorption of plasminogen–mAb com-
Table 1
SPR binding affinity of plasminogen and its derivatives to mAbs
Plasminogen K1 + 2 + 3 K4
A10.2 13F 0.65 – 5.6F 0.6
CPL15 32F 0.5 5.8F 0.6 –
Dissociation constants (Kd, nmol/l) as calculated by nonlinear regression
analysis in terms of the rectangular hyperbolic relationship (Fig. 2) between
mAb immobilised on a rabbit anti-mouse Fc sensor chip and plasminogen
or its elastase-derived fragments in the flowing solution. These values were
in agreement with those calculated from kinetic data.
Fig. 1. On-chip fibrinogen to fibrin transformation with a-thrombin.
Fibrinogen was immobilized on a pioneer C1 sensor chip (17000 RU,f 50
fmol/mm2) using glutaraldehyde chemistry. Active a-thrombin (0.1 Amol/l)
was flowed on the immobilized fibrinogen at a flow rate of 2 Al/min. The
main figure shows a typical on-chip digestion sensorgram. The initial
response gradually lowered with time of a-thrombin delivery to the sensing
flow cell. The decrease in the baseline resonance after the end of a-
thrombin injection (31725! 30790) indicated that proteolytic conversion
of fibrinogen to fibrin had occurred. Inset: Release of fibrinopeptide A by
a-thrombin as monitored with a monoclonal antibody (Y18) directed
against the Aa stretch 1–51 of human fibrinogen [35]. Bars represent the
binding response of Y18 to immobilized fibrinogen before delivery of
active a-thrombin (open bars) and after five successive injections of active
a-thrombin (filled bars).
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Fig. 2. Analysis of the binding of plasminogen to fibrin surfaces by SPR. Plasminogen was injected at the indicated concentrations over fibrin coated on
glutaraldehyde-activated pioneer C1 sensor chips. The figure shows plots of RU values at varying plasminogen concentrations. (.) Total binding, (4) binding
to an uncoated flow cell, (n) specific binding. The solid lines represent the best nonlinear least square fit of the data to the rectangular hyperbolic binding
equation (Eq. (2)). For this typical experiment, the calculated dissociation constant was: Kd = 0.97 AM. Inset: Determination of the inhibition constant (Ki) of 6-
Ahx on the binding of plasminogen to the fibrin sensor chip (25 nm,n; 46 nmol/l,5; 92 nmol/l, .; 184 nmol/l,o). The inhibition constant (Ki = 0.112 mmol/l)
was calculated at the intercept of the linear regression analysis of 1/bound versus 6-Ahx concentration. Data points are the average of triplicate experiments.
Fig. 3. SPR analysis of the effect of mAbs IgG or Fab on plasminogen binding to a fibrin sensor chip. Fibrin sensor surfaces were prepared as indicated in
Materials and methods. Plasminogen (25 nmol/l, final concentration) was incubated with mAbs or Fab fragments at the indicated concentrations and was then
injected over the sensing flow cell. The figure shows the relative response (RU) versus concentration for (n) CPL15–plasminogen, (.) A10.2–plasminogen
or (y) A10.2 Fab–plasminogen complexes. The response for the reference uncoated cell was subtracted from that of the fibrin-coated cell. Elution of
plasminogen–mAbs complexes was performed with 200 mmol/l 6-Ahx. Inset. Analysis of r-apo(a) sensitivity to mAb A10.2 Fab fragment in binding to the
fibrin sensor chip. RU values for r-apo(a) binding are plotted against the concentration of Fab. The solid line represents nonlinear analysis fitting of data points
in terms of a hyperbolic decay relationship with the calculated parameter IC50 = 0.02 Amol/l, the concentration of Fab fragment that decreases by 50% the
binding of r-apo(a) to the fibrin sensor chip.
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plexes as a function of mAb concentration. The data clearly
show a linear relation between adsorption of the complexes
and mAb concentration in the range studied. A control IgG
had no effect on plasminogen binding to fibrin and injection
of mAbs alone resulted in no detectable binding. The linear
increase in plasminogen binding with mAb concentration
suggests a bivalent binding model for the mAbs and the
formation of plasminogen–mAb–plasminogen complexes.
Therefore, to asses whether the promoter effect of mAbs on
plasminogen binding to fibrin requires antibody bivalency,
the effect of papain-derived mAb A10.2 FAb fragments on
the binding of plasminogen to fibrin was studied. The Fab
fragments were functionally active as indicated by their high
affinity for plasminogen (Kd = 3 nmol/l, data not shown) and
their ability to inhibit apo(a) binding to fibrin (inset of Fig.
3) in a concentration-dependent manner (IC50 = 0.02 Amol/
l). As shown in Fig. 3, Fab fragments did not promote
plasminogen binding to the fibrin-coated sensor chip indi-
cating that monovalent binding results in plasminogen–Fab
complexes that do not promote enhancement of plasmino-
gen binding.
If mAb bivalency is required for enhanced plasminogen
binding, in excess of antibody, the interaction with the
antigen may reach equivalency and promotion of binding
should not occur. This hypothesis was explored by studying
the effect of up to 250 nmol/l CPL15 on the binding of 25
nmol/l plasminogen to the fibrin sensor chip. When CPL15
was flowed at concentrations between 0 and 250 nmol/l, in
the absence of plasminogen, no binding could be detected.
Plasminogen at 25 nmol/l in the absence of CPL15 pro-
duced, as expected (Fig. 4), a response of f 12 RU, that is,
f 0.13 fmol of plasminogen bound per square millimeter of
fibrin surface. At low mAb concentrations, < 2 nmol/l, a
linear response similar to that shown in Fig. 3 was obtained
until a maximum (f 58 RU) was reached at a concentration
of about 3 nmol/l mAb (f 5-fold increase over control IgG
or plasminogen alone). However, at higher concentrations,
the amount bound decreased progressively with increasing
concentrations of mAb CPL15 until a plateau value similar
to that of plasminogen alone was obtained. When the same
mixtures of plasminogen and mAb were incubated with
fibrin in a static system and the amount of plasminogen
bound was detected by measuring the release of pNa from
CBS 0065 in the presence of t-PA (see below), an identical
bell-shaped profile was obtained (not shown). A control IgG
did not significantly affect the binding of plasminogen to
fibrin. The inset of Fig. 4 shows identical effects of mAb
CPL15 on the binding of the plasminogen fragment kringle
1 + 2 + 3 to fibrin. Altogether, these results indicate that the
interaction of either plasminogen or its K1 + 2 + 3 fragment
with mAb CPL15 follows a bivalent mechanism that
explains the increase in plasminogen binding to fibrin.
3.4. Effect of mAbs on plasmin generation and fibrinolysis
The model of a fibrin surface used in these experiments
allows quantitation of plasmin generation by measuring
either the progress of hydrolysis of a chromogenic substrate
selective for plasmin or the radioactivity bound. Plasmino-
gen (150 nmol/l final concentration) containing f 4 to 8
nmol/l radiolabelled plasminogen as a tracer, was activated
by fibrin-bound t-Pa in the presence of various concentra-
Fig. 4. SPR analysis of the effect of mAb CPL15 on binding of plasminogen to the fibrin sensor chip. MAb CPL15 and plasminogen at respectively 0–250
and 25 nmol/l final concentrations were incubated for 30 min at room temperature. A volume of 10 Al of each mixture was then injected over the fibrin
sensor surface. The binding response is plotted versus the concentration of mAb. Inset: Fibrin binding isotherm of plasminogen fragment K1 + 2 + 3 obtained
by varying mAb (0–250 nmol/l) at a fixed concentration of K1+ 2 + 3 (25 nmol/l). Elution of plasminogen–mAbs complexes was performed with 0.2 mol/l
6-Ahx.
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tions of either mAbs (CPL15, A10.2) IgG1 or Fab frag-
ments. Controls included were a P3X63 myeloma IgG and a
sample of plasminogen in buffer with no added mAb. The
amount of plasmin generated at the surface of fibrin at each
time point was detected at the end of the activation experi-
ment. A linear increase in the amount of plasmin formed as
a function of time was measured with both the chromogenic
substrate assay (activity of plasmin) and by counting the
radioactivity (mass of protein bound, Fig. 5). In all cases
(controls, absence or presence of mAbs), the amount of
plasmin formed at the surface of fibrin increased as a
function of time throughout the activation period. However,
the amount of plasmin generated in the presence of mAbs
was significantly increased at the concentrations of 15 and
100 nmol/l. Indeed, plasmin formation occurred at a 10-fold
higher activation rate at a concentration of 100 nmol/l mAb
CPL15 or A10.2 (165 and 181 fmol/min, respectively) than
in the presence of the control IgG (26.4 fmol/min). Of note
that at a mAb concentration of 500 nmol/l, the amount of
plasmin formed was lower than in the presence of 15 nmol/l
mAb and approached the control values. In contrast, the
profile obtained at the different Fab fragment concentrations
tested was in all cases similar to that obtained with controls
(Fig. 6). The progressive increase in protein mass of
plasmin(ogen) bound to fibrin during the activation experi-
ments was parallel to the increase in plasmin activity as
measured with the chromogenic substrate assay. Altogether,
these results indicate that the increase in plasmin activity
was due to an increase in the amount of plasminogen bound
to the surface of fibrin.
3.5. Detection of monoclonal antibodies at the fibrin surface
In parallel experiments, after quantification of fibrin-
bound plasmin activity, the surface was probed with a
peroxidase-labelled-goat-anti-mouse IgG at a proper dilu-
tion. Fig. 6 shows typical plasminogen activation kinetics in
the presence of mAb A10.2. When this mAb was incubated
with fibrin in the absence of plasminogen at concentrations
identical to those used in the activation experiments, it did
not bind to fibrin. In contrast, in the presence of plasmi-
nogen, the increase in plasmin formation over controls, at
each time point during the activation process, was simulta-
neously associated with a progressive increase in binding of
the mAb.
4. Discussion
The purpose of these studies was to investigate the
mechanism by which mAbs directed against plasminogen
enhance the rate of plasmin formation at the surface of
fibrin, that is, fibrinolysis. It has been reported that some
Fig. 5. Effect of CPL15 mAb on plasminogen activation at fibrin surfaces.
Plasminogen activation experiments were performed under static conditions
using fibrin surfaces incubated with t-Pa at 50 IU/ml. Excess t-PA was
discarded and the reaction was started by adding 50 Al per well of the
activation solution for the indicated times. The activation solution was
purified plasminogen (150 nmol/l) supplemented with a trace amount (4
nmol/l final concentration) of 125I-plasminogen in assay buffer (q) and one
of the following mAb CPL15 at (w ) 15 nmol/l, (n) 100 nmol/l and (.) 500
nmol/l, or non-immun P3X63 IgG at (E) 100 nmol/l. The time course of
the activation was followed at regular intervals at 37 jC. The wells were
dried, cut off and the radioactivity counted in a g-radiation counter. The
bound radioactivity was converted into femtomoles of plasmin(ogen) bound
per well as calculated from the molar radioactivity of the plasminogen input
solution, and plotted versus the activation time.
Fig. 6. Effect of mAb A10.2 IgG and Fab fragment on plasminogen
activation by fibrin-bound t-PA. The procedure for activation was as
described in Fig. 5. The activation mixture was assay buffer containing 150
nmol/l Glu-plasminogen alone (o) or supplemented with one of the
following: Fab fragments at 15 nmol/l (q), or 100 nmol/l (D), mAb A10.2
at 15 nmol/l (n) or non-immun IgG at 15 nmol/l (w ). The reaction was
stopped by removing the fluid phase at the indicated times, and plasmin
generated at the fibrin surface was measured by addition of 1.5 nmol/l CBS
0065. The release of p-nitroaniline from the substrate was monitored at 37
jC in a microtitration plate counter at a double-wavelength absorbance ratio
(A405/490 nm). Initial velocities for each time point are given in v=(D405/
min)103. Fibrin surfaces onto which plasminogen activation was performed
in the presence of 15 nmol/l mAb A10.2 IgG (n) were further probed with
a goat anti-mouse horseradish peroxidase-labelled IgG (5). Data points
represent the average of duplicate determinations from three different
experiments. Intra-assay and inter-assay coefficients of variation derived
from measurements of plasmin activity were 2.5F 0.1 and 8.1F 0.2,
respectively.
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mAbs directed against plasminogen kringles may induce 6-
Ahx-like conformational changes that increase the rate of
plasmin formation [46–48]. However, mAbs may exert
their effects on plasmin formation at surfaces through an
other mechanism which is intrinsic to antibody structure:
ligand bivalency. This possibility is evoked by studies with
anti-phospholipid antibodies and their effect on thrombin
production [16].
Thrombin production, the counterpart of surface-con-
trolled plasmin formation, involves the clustering of phos-
pholipid-binding proteins on activated platelets. Bivalent
binding of anti-phospholipid antibodies can increase throm-
bin production through enhancement of prothrombin bind-
ing by formation of clusters [17,18]. A similar bivalent
mechanism has been proposed for the anti-phospholipid
antibody-induced enhanced binding of h2-glycoprotein l to
phospholipid surfaces [19–22]. Therefore, an alternative
explanation to the conformational changes hypothesis on
the enhancement of plasmin formation by mAbs would be
enhanced plasminogen binding through antibody bivalency.
In the present work, we have evaluated this mechanism
using mAbs directed against distinct domain of the plasmi-
nogen molecule: A10.2, a mAb that reacts with the LBS of
kringle 4 [23], and CPL15, a mAb directed against plasmi-
nogen kringle 1 [24]. Affinities of these mAbs for plasmi-
nogen and the corresponding fragments were in the low
nanomoles per liter range (Kd = 10 nmol/l for A10.2 and
Kd = 32 nmol/l for CPL15). We have explored the effect of
these mAbs on the binding of plasminogen to well-charac-
terised fibrin surfaces that support plasminogen binding and
activation [27,29]. We have now developed the preparation
of these fibrin surfaces in sensor chips for SPR studies. The
immobilised fibrinogen was enzymatically digested on the
sensor chip by delivering thrombin to the sensing flow cell,
through the microfluidic system. After on-chip digestion, a
fibrin surface was obtained that binds plasminogen and r-
apo(a) with affinities similar to those previously determined
in other systems (Kdf 1 Amol/l and Kdf 50 nmol/l,
respectively). The mAb A10.2 blocks the LBS of kringle
4 and behaves in that way as a lysine analogue. However,
plasminogen contains a distinct LBS in kringle 1 that is not
affected by mAb A10.2 and ensures its binding to fibrin.
mAb CPL15 recognises a region in kringle 1 of plasmino-
gen that does not interfere with its fibrin-binding function.
Both mAb A10.2 and mAb CPL15 increased the rate of
plasmin formation at the surface of fibrin in a concentration-
dependent manner.
The possibility that this enhancing effect may be due to
an increase in plasminogen binding was explored in the
present work as follows. The assembly on plasminogen of
fibrin in the presence of mAbs was studied by SPR under
flow conditions. The kinetics of the formation of plasmin on
fibrin surfaces was studied in parallel. The results of these
studies demonstrate a parallel increase in both the mass of
plasminogen bound and the enhancement of plasmin for-
mation. Indeed, a linear increase in the binding of plasmi-
nogen to the fibrin surface was observed with increasing
concentrations of the mAbs until a maximum was reached.
This effect was immediately followed, at higher mAb
concentrations, by a regression in the amount bound until
a level similar to that observed in the absence of mAbs was
reached. Because mAb CPL15 does not interfere with the
fibrin-binding function of kringle 1, a similar bell-shaped
isotherm could be obtained when the K1 + 2 + 3 plasmino-
gen fragment was used. This effect could not be obtained
with isolated plasminogen kringle 4 since mAb A10.2
inhibits its binding to fibrin by blocking its LBS.
We hypothesize (Fig. 7) that the bell-shaped isotherm
was due to the formation of bivalent ternary and monovalent
binary complexes at the varying plasminogen/mAb ratios
Fig. 7. Proposed bridging mechanism for mAb-induced increase in plasminogen binding to fibrin and plasmin formation. Plasminogen interacts with lysine
residues in fibrin with dissociation constant, Kd = 0.92 Amol/l, and with mAbs directed against kringle 1 (CPL15, Kd = 5.8 nmol/l) and kringle 4 (A10.2,
Kd = 5.6 nmol/l). According to experimental data in Figs. 3 and 4, bivalency of mAbs induces the formation of ternary complexes at high mAb/plasminogen
ratios (excess plasminogen, low mAb) and increases thereby the amount of plasminogen bound to the surface of fibrin. A possible interpretation for this
findings is that the mAbs may function as a bridge between one molecule of plasminogen bound to fibrin and another molecule of plasminogen in the soluble
phase. Our data do not discard, however, the possibility that the two molecules of plasminogen engaged with one molecule of mAb in the formation of the
ternary complex, may be bound to fibrin.
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studied, an effect not uncommon in antibody studies and
most probably a consequence of antibody bivalency [49]. In
the proposed model, at a fixed plasminogen concentration,
the formation of plasminogen–mAb–plasminogen ternary
complexes able to bind to fibrin increases with the pro-
gressive increase in mAb concentration. The maximum
concentration of ternary complexes formed, and therefore
the maximal amount of plasminogen detected at the fibrin
surface, is reached when the concentration of plasminogen
and mAb attains equivalency. With further increases in the
concentration of mAb, the formation of ternary complexes is
reduced and the interaction is shifted to the formation of
plasminogen–mAb binary complexes which results in the
observed decrease in the amount of plasminogen detected at
the fibrin surface. As a matter of fact, mAbs were found at
the fibrin surface in a concentration-dependent manner only
in the presence of plasminogen. Bivalency of mAbs may
therefore function as a bridge between two molecules of
plasminogen, one molecule being bound directly to fibrin
and the other in the fluid phase. To test this hyphothesis, Fab
fragments were examined for their ability to promote
plasminogen binding to fibrin. First, we demonstrated that
the A10.2 Fab fragments were functionally active as indi-
cated by their ability to inhibit apo(a) binding to fibrin
(IC50 = 20 nmol/l). No increase in the binding of plasmi-
nogen was observed with increasing concentrations of the
Fab fragments, indicating that bivalency of mAbs was the
operating mechanism required for enhanced plasminogen
binding to fibrin.
The possibility that the bridging model may be operating
with two molecules of plasminogen bound to fibrin (cluster-
ing) as in the prothrombin and h2-glycoprotein l models
[18,20,22] cannot be ruled out. However, in that model,
binding of the antibodies to different epitopes may result in
complexes of various sizes and stoichiometries, and their
low affinity (micromoles per liter range) for prothrombin
may favor clustering. In contrast, in our fibrin binding
model, the plasminogen–mAb interaction is of high affinity
(nanomoles per liter range), monospecific by definition, and
the low plasminogen density that may be obtained at the
concentration used (25 nmol/l, 40-fold lower than its f 1
Amol/l Kd for fibrin), may fail to promote plasminogen
clustering. Furthermore, since the concentration of plasmi-
nogen bound to fibrin is governed by the affinity of the
interaction, bivalency of the mAb toward two plasminogen
molecules will not result in increased plasminogen binding.
In agreement with these concepts, the bell-shaped isotherm
was skewed to very low mAb concentrations indicating that
(1) the affinity of mAb for plasminogen was the determinant
factor in bringing supplementary molecules of plasminogen
to the fibrin surface and (2) that this phenomenon was
independent of the affinity of plasminogen for fibrin.
The bridging effect of mAbs on plasminogen is further
substantiated by time course plasminogen activation experi-
ments at the surface of fibrin. The kinetics of plasmin
formation at the surface of fibrin was detected by measuring
both the mass of plasmin formed and its amidolytic activity.
The t-PA was first bound to the fibrin surface, a condition
that may be equivalent to the binding of circulating t-PA to
the surface of a clot. A mixture of mAbs and Glu-plasmi-
nogen was used for the activation experiments. The sub-
sequent appearance of plasminogen derivatives and the
binding of mAbs or Fab was determined as the fibrin was
degraded. This experimental setup was similar to the one
previously described to isolate the effect of Lp(a) on plas-
minogen activation [13], and offered the additional advant-
age to measure plasmin(ogen) and monoclonal antibodies on
the same surface of fibrin using specific antibodies and a
chromogenic substrate assay. As for plasminogen binding,
the ability of mAbs to enhance plasmin formation was
concentration dependent until a maximum was reached. At
a high mAb concentration (500 nmol/l), the amount of
plasmin formed decreased toward levels measured in the
absence of mAbs.
Although our data underscore the importance of antibody
bivalency, they do not exclude the possibility that mAb may
induce conformational changes as well. However, such
conformational changes are not required to explain the
binding and kinetics of plasminogen activation. Indeed, if
binding of mAbs to plasminogen was solely to induce
conformational changes that increase the rate of plasmin
formation, the interaction with Fab fragments should have
been equivalent. The absence of role of Fab fragments
indicates that the effect of mAb is mainly due to bivalency.
In conclusion, our data support a model (Fig. 7) for
mAbs enhancement of plasminogen binding and plasmin
formation in which mAb bivalency engages one molecule of
plasminogen bound to fibrin and another plasminogen
molecule from the fluid phase. This mechanism is different
from the cross-linking clustering mechanism proposed for
the enhancement of h2-glycoprotein l binding by anti-
phospholipid antibodies.
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